Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1Carcinoma in Situ 1

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × dodecyl maltoside × Clear all
NCT07283835 2026-04-23

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Lepu Biopharma Co., Ltd.

Phase 2 Recruiting
16 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡